Treatment Options and Day-to-Day Management
At a Glance
Choreoacanthocytosis has no treatment that stops its progression, so care focuses on symptoms and safety. Specialists may tailor mouth protection and swallowing support, seizure treatment, physical and occupational therapy, and, in selected severe cases, deep brain stimulation.
Living with VPS13A disease requires a focus on quality of life and safety, as there is currently no “disease-modifying” treatment that can stop the underlying progression [1]. Instead, care is symptomatic, meaning your medical team works to address each specific symptom as it arises through a multidisciplinary approach [2].
Managing Orolingual Dystonia and Biting
The forceful, involuntary biting of the tongue and cheeks is one of the most distressing features of the disease. While no single approach works for everyone, several options are used in practice:
- Botulinum Toxin: Injections (like Botox) into the jaw muscles (masseters and pterygoids) can help weaken the force of involuntary jaw-closing and biting [3]. These are often evaluated using EMG-guidance. However, botulinum toxin should be presented as an individualized specialist treatment with limited disease-specific evidence, carrying a risk of causing chewing, jaw, or swallowing weakness [4].
- Dental Protection: Specialized mouthguards or dental devices may be used to protect the tongue and cheeks from injury during episodes [5]. Any protective oral appliance must be custom-fitted and reviewed by an experienced dentist and swallowing clinician because a mouthguard can itself affect chewing or swallowing. (Safety Note: Never place a loose object, like a towel, in the mouth as a sensory trick, as this creates an immediate choking, aspiration, and airway-obstruction hazard).
Strategies for Swallowing and Nutrition
Because involuntary movements can cause food to be pushed out of the mouth or inhaled into the lungs (aspiration), managing dysphagia (swallowing difficulty) is a top priority [6].
- Dietary Changes: Texture, posture, bite size, pacing, and oral feeding decisions must be individualized by a speech-language pathologist, ideally after a clinical or instrumental swallow assessment (like a VFSS or FEES). Purees or thickened liquids are not universally safer and can sometimes cause residue or dehydration.
- Enteral Feeding: If weight loss becomes significant or if the risk of aspiration pneumonia is high, your team may discuss a PEG tube (a feeding tube placed through the abdomen) [7]. This is a shared-decision regarding your goals of care. A PEG can support nutrition and hydration, but it does not reliably prevent aspiration of saliva, secretions, or reflux, and does not eliminate aspiration pneumonia. Furthermore, tube feeding does not automatically mean all oral intake must stop, if deemed safe and desired [7].
Movement Control and Deep Brain Stimulation (DBS)
If chorea (irregular limb movements) or dystonia (stiff, twisting postures) becomes severe and does not respond well to medications, Deep Brain Stimulation (DBS) may be considered at an expert center [8].
- The Procedure: This involves surgically placing electrodes into a specific part of the brain (the globus pallidus interna or GPi) to regulate abnormal electrical signals [9].
- Expected Outcomes: While the evidence in this ultra-rare disease comes mostly from small case reports and series, some carefully selected patients with severe, medication-refractory symptoms see reductions in chorea and oromandibular dystonia [8][9]. However, DBS is not disease-modifying, carries surgical risks, and is not expected to improve progression, neuropathy, cognition, or swallowing. Speech problems (dysarthria) often do not improve with DBS and may sometimes even worsen slightly after surgery [8].
Seizure and Mobility Management
Seizures in VPS13A disease can be frequent or difficult to control, requiring individualized treatment with anti-epileptic drugs (AEDs) [10]. Because the disease can also cause peripheral neuropathy (nerve damage) and muscle wasting, keeping mobile is essential [10].
- Seizure Care: There is no “one-size-fits-all” medication. Doctors may use various AEDs (such as carbamazepine for some focal seizures) but the choice must be made by an epilepsy clinician according to your seizure type, EEG, and comorbidities, as some drugs can aggravate certain generalized syndromes [11]. Medications should not be started, stopped, or changed without your prescriber. It is vital to have a clear “rescue plan” for clusters of seizures [12].
- Physical and Occupational Therapy: Regular PT and OT are crucial for managing gait instability and preventing falls [2]. Therapists can also recommend assistive devices and home modifications to keep you safe as your mobility changes [13].
Common questions in this guide
Is there a treatment that stops VPS13A disease from progressing?
Can Botox help with biting and jaw dystonia in choreoacanthocytosis?
How can swallowing problems and aspiration risk be managed?
Does a PEG feeding tube prevent aspiration pneumonia?
Could deep brain stimulation help chorea or dystonia?
How are seizures and mobility problems treated in VPS13A disease?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Choreoacanthocytosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Should we consider EMG-guided botulinum toxin injections for my oromandibular dystonia, and what are the risks to my chewing and swallowing?
- 2.Can you refer me to a Speech-Language Pathologist for an instrumental swallow assessment to evaluate my specific oral feeding safety?
- 3.Is my current seizure medication the most appropriate choice given my specific seizure type and movement symptoms?
- 4.Would I be a candidate for Deep Brain Stimulation (DBS) at an expert center if my chorea or dystonia becomes unmanageable with medications?
- 5.Can we coordinate a multidisciplinary care team including a neurologist, a speech therapist, and a physical therapist who can collaborate on my care?
References
References (13)
- 1
Management of Neuroacanthocytosis Syndromes.
Walker RH
Tremor and other hyperkinetic movements (New York, N.Y.) 2015; (5()):346 doi:10.7916/D8W66K48.
PMID: 26504667 - 2
Two case reports of chorea-acanthocytosis and review of literature.
Huang S, Zhang J, Tao M, et al.
European journal of medical research 2022; (27(1)):22 doi:10.1186/s40001-022-00646-7.
PMID: 35130982 - 3
Progress in the Diagnosis and Management of Chorea-acanthocytosis.
Liu Y, Liu ZY, Wan XH, Guo Y
Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 2018; (33(1)):53-59 doi:10.24920/21802.
PMID: 29620515 - 4
Management of oromandibular dystonia on a chorea acanthocytosis: a brief review of the literature and a clinical case.
Ortega MC, Skármeta NP, Diaz YJ
Cranio : the journal of craniomandibular practice 2016; (34(5)):332-7 doi:10.1179/2151090315Y.0000000027.
PMID: 26431448 - 5
Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up.
Dulski J, Sołtan W, Schinwelski M, et al.
Clinical neurology and neurosurgery 2016; (147()):78-83.
PMID: 27310290 - 6
A Man With Progressive Chorea and Abnormal Trunk Movements.
Sugumaran R, Bhuvaneswaran R
Cureus 2024; (16(6)):e62004 doi:10.7759/cureus.62004.
PMID: 38989367 - 7
Case report: Neuroacanthocytosis associated with novel variants in the VPS13A gene with concomitant nucleotide expansion for CANVAS and assessment with osmotic gradient ektacytometry.
Paucar M, Wincent J, Rubin C, et al.
Frontiers in neuroscience 2024; (18()):1409366 doi:10.3389/fnins.2024.1409366.
PMID: 39416949 - 8
Deep brain stimulation for chorea-acanthocytosis: a systematic review.
Wu Y, Xu YY, Gao Y, et al.
Neurosurgical review 2022; (45(3)):1861-1871 doi:10.1007/s10143-022-01735-1.
PMID: 35020105 - 9
Pallidus Stimulation for Chorea-Acanthocytosis: A Systematic Review and Meta-Analysis of Individual Data.
He W, Li C, Dong H, et al.
Journal of movement disorders 2022; (15(3)):197-205 doi:10.14802/jmd.22003.
PMID: 35880382 - 10
The Diverse Neuromuscular Spectrum of VPS13A Disease.
Buchberger A, Riedel E, Hackenberg M, et al.
Annals of clinical and translational neurology 2026; (13(1)):157-169 doi:10.1002/acn3.70198.
PMID: 41030128 - 11
A chorea-acanthocytosis patient with novel mutations in the VPS13A gene without acanthocyte.
Jin S, Sun Z, Fang X, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2024; (45(5)):2057-2061 doi:10.1007/s10072-023-07174-0.
PMID: 37985634 - 12
Life expectancy and mortality in chorea-acanthocytosis and McLeod syndrome.
Walker RH, Miranda M, Jung HH, Danek A
Parkinsonism & related disorders 2019; (60()):158-161 doi:10.1016/j.parkreldis.2018.09.003.
PMID: 30245172 - 13
Progressive ataxia and orolingual chorea revealing a novel VPS13A variant: a case report of chorea-acanthocytosis without peripheral acanthocytosis with a literature review.
Ouskri A, Bouhda N, Khaissidi K, et al.
Neurogenetics 2026; (27(1)).
PMID: 42631781
This page describes treatment and daily management options for choreoacanthocytosis for educational purposes only; it is not medical advice. Decisions about swallowing, seizures, procedures, and feeding should be made with your own specialist team.